Nuclear Medicine Market Synopsis

Nuclear Medicine Market Size Was Valued at USD  14.11 Billion in 2023 and is Projected to Reach USD  41.38 Billion by 2032, Growing at a CAGR of 12.70% From 2024-2032.

Most related to nuclear medicine– is the branch of medicine that employs radioactive substances, called radiopharmaceuticals, to image or treat diseases. It is a type of material that is administered in the body through intravenous, oral or inhalation administration and settles in target organs/tissues. These items release energy in the form of rays that specialized cameras and imaging procedures can pick up and use to produce pictures of the internal organs and their activity. Nuclear medicine also entail procedures which entails the use of radioactive materials in treating ailments for instance thyroid condition, cancer and management of pain. Is vital for the diagnosis and follow-up of pathologies at molecular level providing a thorough understanding of the body’s performances.

• Nuclear medicine market refers to a group of medical procedures and technologies that rely on the use of radiation substances for medical diagnosis and treatment. This field has been evolving and developing in the past few years due to technical improvement, raising incidence of chronic diseases, and patient preference towards noninvasive procedures.
• In nuclear medicine diagnostics, certain drugs containing radioactive substances are given to the patients and the functioning of organs and presence of diseases can be traced by observing their reaction to the given medicine. Methods like Single photon emission computed tomography (SPECT), positron emission tomography (PET) are very useful for imaging the functional activities of different organs and tissues at a molecular level. PET-CT involves integration of PET technology with computed tomography and offers both molecular and structural information in cancer, neurological disorders and cardiovascular diseases’ diagnosis and early localization. This capability has drastically transformed oncology by allowing accurate staging of the disease and its treatment thereby contributing to the principles of precision medicine.
•  However, not only diagnostics are important within the nuclear medicine therapeutic area. Iodine-131, lutetium-177 are examples of radioactive isotopes which can be used in targeted therapies for cancer. This is called radiotherapy; it focuses radiation beams directly on the cancer cells with the least amount of effect on the healthy tissue. This targeted precision increases the quality of the treatment and also decreases side effects as opposed to traditional radiation therapies.
•  There are various aspects that has laid foundation to the expansion of the nuclear medicine market. Modern progress in technology and imaging density as well as radiopharmaceutical production always extend the sphere of nuclear medicine activity. The emerging concepts of particular treatments based on genetics and molecular screening add on pressure towards methodologies directed towards early and efficient disease identification. Also, in the current world, populations are aging, and with this comes a high prevalence of chronic diseases like cancer and cardiovascular diseases more so with a demanding need for better diagnostic and treatment methods.
• However, the nuclear medicine market is not without these challenges as would be discussed below. These are many barriers such as regulatory challenges in embracing the new Radiopharmaceuticals, issues of handling and transporting radioactive materials also the cost of equipment and the procedures. Also, issues of radioactivity and safety continue to be relevant in the treatment of patients, as well as in the view of the public.
•  As for the outlook of nuclear medicine, there is more market development and technological advancement can be expected in the near future. The topics and progress to the next levels of imaging can be summarized as follows: Improvements in imaging equipment includes detector sensitivity and system resolution; new developments in radiopharmaceutical composition and target specific therapies foresee higher diagnostic yield and improved therapeutic efficacies. Such integration with AI and machine learning is also anticipated to enhance image interpretation and, therefore, treatment consultation and planning, which, in turn, will make the field move toward increased accuracy and individualized medical procedures.
•  Thus, nuclear medicine is a progressive and constantly developing field in the sphere of healthcare, which employs radioactive tracers and isotopes for differential diagnostics and subsequent therapy. As it has been witnessing regular improvements in technologies on one hand and expanding its clinical use on the other, nuclear medicine remains as one of the most important areas in the healthcare industry that can significantly contribute towards enhancing the quality of patient’s care and defining the future of medical imaging and therapeutic interventions.

Nuclear Medicine Market Trend Analysis

Shift towards Digital Imaging and AI

• The Nuclear Medicine Market is in the process of change with Digital Imaging also the use of Artificial Intelligence (AI). Diagnostic technologies such as PET scan and SPECT scan have contributed tremendously through digital imaging to show a molecular image of the biological system. These developments help in increasing the detection rates of diseases which in turn constitute to the improvement of the patient’s health due to proper medication and treatment planning.
•  AI is proving to be valuable as it can evaluate large datasets of images and detection of patterns/abnormalities that can be missed by the human eye. In addition to using this capability to diagnose a particular disorder, assessment of the extent and probable future evolution of the pathology and its reaction to treatment can be accomplished as well. Furthermore, the application of artificial intelligence is also helpful and increasing the effectiveness and efficacy of the nuclear medicine departments by minimizing the operational costs and time for various recurrent and repetitive tasks. With more involving digitization in the healthcare industry, the application of digital imaging and artificial intelligence in nuclear medicine is set to enhance technological advances, patients’ experience, and clinical practices in future.

Integration of Artificial Intelligence (AI) in Nuclear Medicine

• Artificial Intelligence (AI) is gradually implementing itself into the Nuclear Medicine market from the aspect of imaging in technologies as well as diagnostics. It is evidenced that AI helps in improving the precision and expedience of image analysis, more specifically in fields, such as PET and SPECT where identification and measurement of molecular occurrences are requisite. AI Speech & Image Analysis can compute variations which even human eyes may never notice and diagnose diseases in their early stage such as cancer, cardiovascular and neurological diseases.
•   Furthermore, using big data, AI is enhancing the prescriptive treatment plans meaning that it looks at a patient database and prescribes which treatment will most likely work and have least side effects. It also plays a crucial role in the internal functioning of nuclear medicine divisions and affordable diagnosis and treatment. However, the significant progress of AI in the future will contribute to the further development of nuclear medicine and the enhancement of the therapeutic and diagnostic imaging systems in the health care facilities.

Nuclear Medicine Market Segment Analysis:

Nuclear Medicine Market Segmented based on Product Type, Application, and End-User.

By Product  Type, Diagnostics  segment is expected to dominate the market during the forecast period

• The Nuclear Medicine Market has two main segments of products, diagnostics and therapeutics, which define the direction of developments in the market. Diagnostics is an umbrella that covers a number of imaging methods such as SPECT and PET necessary in cancer, cardiovascular and neurological diseases’ diagnosis, among others. These imaging techniques involve the use of radiotracers or radiopharmaceuticals to study physiological activities in the body as compared to ordinary imaging methods.
• While diagnostcs in nuclear medicine are based on administstion of radiopharmaceuticals for imaging of organs, thetherapeutic applications involve their use to treat disease by delivering radioisotopes to cancer cells to kill them, without affecting the healthy tissue. The market is trending in concern to innovation, as new digital imaging technologies alongside machine learning algorithms improves the diagnostics and therefore the treatment. This sector’s growth is also facilitated by a rise in the usage in personalised management since nuclear medicine allows management of affected individuals according to their unique characteristics and diseases. Approved regulations in addition to constant evolutions in exploratory and novel radiotracers are also influencing the using, making nuclear medicine an important constituent of today’s healthcare institutions all over the world.

By Application  , Lymphoma  segment held the largest share in 2023

• The Nuclear Medicine Market is classified by the various application that each of them possess important functions in diagnosis and treatment processes. Cardiology applications focus on the evaluation of heart function and blood flow through methods such as myocardial perfusion images and cardiac PET. Neurology applications are related to understanding the function of the brain, diagnosing illnesses affecting the nervous system, and through the brain lesion localization based on SPECT and PET. Oncology applications are known to be essential for cancer diagnosis, to stage and evaluate the response to therapy using radiopharmaceuticals configured to identify tumors in organs such as the breast, prostate and lung. Thyroid scans entail the use of radioactive iodine as a tool to identify diseases of the thyroid gland for instance hyperthyroidism and thyroid cancer.
•  Lymphoma imaging plays the role of diagnosing and determining the extent of lymphatic system cancers throughout the body, while bone metastasis scans estimate the extent of cancer affecting the bones. Endocrine tumor nuclear medicine is the observation of tumors of the gland – hormone – secreting glands whereas pulmonary scan studies the function of the lungs and identifies disorders like pulmonary embolism. Urology applications are mainly used in the evaluation of kidney functions and identification of abnormalities in the urinary system. Other applications include a broad spectrum of the diagnosis and treatment in such categories as gastrointestinal diseases, infections, inflammation, etc Therefore, it can be seen that nuclear medicine is in great demand in various categories of medicine.

Nuclear Medicine Market Regional Insights:

Asia Pacific  is Expected to Dominate the Market Over the Forecast period

• Over the forecast period Asia Pacific is expected to hold largest share in the nuclear medicine market. This region’s dominance can be attributed to several factors, including; several establishment of the healthcare infrastructure, growing prevalence of chronic diseases including cancers and cardiovascular disorders and increased use of advanced medical imaging. Big countries that consist of a large population base like China, Japan, and India have taken the lead in the market as there is a hike in the expenditures on health care.
•  Also, the increasing use of nuclear imaging at a technological level with the help of artificial intelligence and digital tools is driving the market in the region. Also, positive government measures and reforms, encouraging for improving the availability and affordability of health care, have a positive impact on the growth of the market. The move to incorporate personalizing medications, which is also coupled with a growing customer demand for efficient diagnostic techniques, has also been seen as factors that have influenced the APAC’s uptake of nuclear medicine solutions. In conclusion it can be stated that the development of the health care investments, advancement of technology, as well as the support of the governments, Asia Pacific region is likely to continue playing a dominant role in the nuclear medicine market in the future years.

Active Key Players in the Nuclear Medicine Market

• GE Healthcare (USA)
• Jubilant Life Sciences Ltd (India)
• Nordion (Canada), Inc. (Canada)
• Bracco Imaging S.P.A (Italy)
• The Institute for Radioelements (IRE) (Belgium)
• NTP Radioisotopes SOC Ltd. (South Africa)
• The Australian Nuclear Science and Technology Organization (Australia)
• Eczacıbaşı-Monrol (Turkey)
• Lantheus Medical Imaging, Inc. (USA)
• Eckert & Ziegler (Germany)
• Mallinckrodt (UK)
• Cardinal Health (USA), Other Key Players.

Key Industry Developments in the Nuclear Medicine Market

• In January 2024, Lantheus Holdings, Inc. (Lantheus) recently solidified its position in the U.S. nuclear medicine market through strategic agreements with Perspective Therapeutics, Inc. The agreements include an exclusive licensing option for Perspective's Pb212-VMT-⍺-NET, an advanced therapy for neuroendocrine tumors, and co-development opportunities for early-stage prostate cancer treatments. Lantheus made a substantial upfront payment of USD 28 million in cash. Additionally, Lantheus plans to acquire up to 19.9% of Perspective's common stock, investing approximately $33 million, pending a qualified third-party financing transaction.  In a reciprocal move, Perspective aims to purchase Lantheus' radiopharmaceutical manufacturing facility in Somerset, New Jersey, enhancing its foothold in the competitive landscape.
• In March 2024, the Ministry of Health of the Republic of Serbia and Rosatom State Corporation signed a Memorandum of Understanding (MoU) regarding cooperation in nuclear medicine. This cooperation is expected to boost market growth over the forecast period.
• In December 2023, Bristol Myers Squibb has agreed to acquire RayzeBio for USD 4.1 billion. RayzeBio is currently conducting clinical trials for two potential cancer therapies using actinium-255. In addition, Point, a company associated with RayzeBio, has two lutetium-177 therapies undergoing phase 3 trials. This acquisition reflects Bristol Myers Squibb's strategic move to expand its portfolio.
• In April 2023, the U.S. FDA approved Novartis’ Milburn facility for the commercial production of Pluvicto. The facility is anticipated to boost the company’s production capabilities.
• In January 2023, NorthStar Medical Radioisotopes notably progressed its technology to produce molybdenum-99 without uranium. This strategic move positions the company at the forefront of the nuclear medicine market, addressing critical supply chain issues.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Nuclear Medicine Market by Product
 4.1 Nuclear Medicine Market Snapshot and Growth Engine
 4.2 Nuclear Medicine Market Overview
 4.3 Diagnostics
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Diagnostics: Geographic Segmentation Analysis
 4.4 Therapeutics
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Therapeutics: Geographic Segmentation Analysis

Chapter 5: Nuclear Medicine Market by Application
 5.1 Nuclear Medicine Market Snapshot and Growth Engine
 5.2 Nuclear Medicine Market Overview
 5.3 Cardiology
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Cardiology: Geographic Segmentation Analysis
 5.4 Neurology
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Neurology: Geographic Segmentation Analysis
 5.5 Oncology
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Oncology: Geographic Segmentation Analysis
 5.6 Thyroid
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Thyroid: Geographic Segmentation Analysis
 5.7 Lymphoma
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Lymphoma: Geographic Segmentation Analysis
 5.8 Bone Metastasis
  5.8.1 Introduction and Market Overview
  5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.8.3 Key Market Trends, Growth Factors and Opportunities
  5.8.4 Bone Metastasis: Geographic Segmentation Analysis
 5.9 Endocrine Tumor
  5.9.1 Introduction and Market Overview
  5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.9.3 Key Market Trends, Growth Factors and Opportunities
  5.9.4 Endocrine Tumor: Geographic Segmentation Analysis
 5.10 Pulmonary Scans
  5.10.1 Introduction and Market Overview
  5.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.10.3 Key Market Trends, Growth Factors and Opportunities
  5.10.4 Pulmonary Scans: Geographic Segmentation Analysis
 5.11 Urology
  5.11.1 Introduction and Market Overview
  5.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.11.3 Key Market Trends, Growth Factors and Opportunities
  5.11.4 Urology: Geographic Segmentation Analysis
 5.12 Othe
  5.12.1 Introduction and Market Overview
  5.12.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.12.3 Key Market Trends, Growth Factors and Opportunities
  5.12.4 Othe: Geographic Segmentation Analysis

Chapter 6: Nuclear Medicine Market by End Use
 6.1 Nuclear Medicine Market Snapshot and Growth Engine
 6.2 Nuclear Medicine Market Overview
 6.3 Hospitals
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Hospitals: Geographic Segmentation Analysis
 6.4 Diagnostic Centers
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Diagnostic Centers: Geographic Segmentation Analysis
 6.5 Others
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Others : Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Nuclear Medicine Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions
  
 7.2 GE HEALTHCARE (USA)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 JUBILANT LIFE SCIENCES LTD (INDIA)
 7.4 NORDION (CANADA) INC
 7.5 (CANADA)
 7.6 BRACCO IMAGING S.P.A (ITALY)
 7.7 THE INSTITUTE FOR RADIOELEMENTS (IRE) (BELGIUM)
 7.8 NTP RADIOISOTOPES SOC LTD (SOUTH AFRICA)
 7.9 THE AUSTRALIAN NUCLEAR SCIENCE
 7.10 TECHNOLOGY ORGANIZATION (AUSTRALIA)
 7.11 ECZACIBAŞI-MONROL (TURKEY)
 7.12 LANTHEUS MEDICAL IMAGING INC
 7.13 (USA)
 7.14 ECKERT & ZIEGLER (GERMANY)
 7.15 MALLINCKRODT (UK)
 7.16 CARDINAL HEALTH (USA)

Chapter 8: Global Nuclear Medicine Market By Region
 8.1 Overview
 8.2. North America Nuclear Medicine Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Product
   8.2.4.1 Diagnostics
   8.2.4.2 Therapeutics
  8.2.5 Historic and Forecasted Market Size By Application
   8.2.5.1 Cardiology
   8.2.5.2 Neurology
   8.2.5.3 Oncology
   8.2.5.4 Thyroid
   8.2.5.5 Lymphoma
   8.2.5.6 Bone Metastasis
   8.2.5.7 Endocrine Tumor
   8.2.5.8 Pulmonary Scans
   8.2.5.9 Urology
   8.2.5.10 Othe
  8.2.6 Historic and Forecasted Market Size By End Use
   8.2.6.1 Hospitals
   8.2.6.2 Diagnostic Centers
   8.2.6.3 Others
  8.2.7 Historic and Forecast Market Size by Country
   8.2.7.1 US
   8.2.7.2 Canada
   8.2.7.3 Mexico
 8.3. Eastern Europe Nuclear Medicine Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Product
   8.3.4.1 Diagnostics
   8.3.4.2 Therapeutics
  8.3.5 Historic and Forecasted Market Size By Application
   8.3.5.1 Cardiology
   8.3.5.2 Neurology
   8.3.5.3 Oncology
   8.3.5.4 Thyroid
   8.3.5.5 Lymphoma
   8.3.5.6 Bone Metastasis
   8.3.5.7 Endocrine Tumor
   8.3.5.8 Pulmonary Scans
   8.3.5.9 Urology
   8.3.5.10 Othe
  8.3.6 Historic and Forecasted Market Size By End Use
   8.3.6.1 Hospitals
   8.3.6.2 Diagnostic Centers
   8.3.6.3 Others
  8.3.7 Historic and Forecast Market Size by Country
   8.3.7.1 Bulgaria
   8.3.7.2 The Czech Republic
   8.3.7.3 Hungary
   8.3.7.4 Poland
   8.3.7.5 Romania
   8.3.7.6 Rest of Eastern Europe
 8.4. Western Europe Nuclear Medicine Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Product
   8.4.4.1 Diagnostics
   8.4.4.2 Therapeutics
  8.4.5 Historic and Forecasted Market Size By Application
   8.4.5.1 Cardiology
   8.4.5.2 Neurology
   8.4.5.3 Oncology
   8.4.5.4 Thyroid
   8.4.5.5 Lymphoma
   8.4.5.6 Bone Metastasis
   8.4.5.7 Endocrine Tumor
   8.4.5.8 Pulmonary Scans
   8.4.5.9 Urology
   8.4.5.10 Othe
  8.4.6 Historic and Forecasted Market Size By End Use
   8.4.6.1 Hospitals
   8.4.6.2 Diagnostic Centers
   8.4.6.3 Others
  8.4.7 Historic and Forecast Market Size by Country
   8.4.7.1 Germany
   8.4.7.2 UK
   8.4.7.3 France
   8.4.7.4 Netherlands
   8.4.7.5 Italy
   8.4.7.6 Russia
   8.4.7.7 Spain
   8.4.7.8 Rest of Western Europe
 8.5. Asia Pacific Nuclear Medicine Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Product
   8.5.4.1 Diagnostics
   8.5.4.2 Therapeutics
  8.5.5 Historic and Forecasted Market Size By Application
   8.5.5.1 Cardiology
   8.5.5.2 Neurology
   8.5.5.3 Oncology
   8.5.5.4 Thyroid
   8.5.5.5 Lymphoma
   8.5.5.6 Bone Metastasis
   8.5.5.7 Endocrine Tumor
   8.5.5.8 Pulmonary Scans
   8.5.5.9 Urology
   8.5.5.10 Othe
  8.5.6 Historic and Forecasted Market Size By End Use
   8.5.6.1 Hospitals
   8.5.6.2 Diagnostic Centers
   8.5.6.3 Others
  8.5.7 Historic and Forecast Market Size by Country
   8.5.7.1 China
   8.5.7.2 India
   8.5.7.3 Japan
   8.5.7.4 South Korea
   8.5.7.5 Malaysia
   8.5.7.6 Thailand
   8.5.7.7 Vietnam
   8.5.7.8 The Philippines
   8.5.7.9 Australia
   8.5.7.10 New Zealand
   8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Nuclear Medicine Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Product
   8.6.4.1 Diagnostics
   8.6.4.2 Therapeutics
  8.6.5 Historic and Forecasted Market Size By Application
   8.6.5.1 Cardiology
   8.6.5.2 Neurology
   8.6.5.3 Oncology
   8.6.5.4 Thyroid
   8.6.5.5 Lymphoma
   8.6.5.6 Bone Metastasis
   8.6.5.7 Endocrine Tumor
   8.6.5.8 Pulmonary Scans
   8.6.5.9 Urology
   8.6.5.10 Othe
  8.6.6 Historic and Forecasted Market Size By End Use
   8.6.6.1 Hospitals
   8.6.6.2 Diagnostic Centers
   8.6.6.3 Others
  8.6.7 Historic and Forecast Market Size by Country
   8.6.7.1 Turkey
   8.6.7.2 Bahrain
   8.6.7.3 Kuwait
   8.6.7.4 Saudi Arabia
   8.6.7.5 Qatar
   8.6.7.6 UAE
   8.6.7.7 Israel
   8.6.7.8 South Africa
 8.7. South America Nuclear Medicine Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Product
   8.7.4.1 Diagnostics
   8.7.4.2 Therapeutics
  8.7.5 Historic and Forecasted Market Size By Application
   8.7.5.1 Cardiology
   8.7.5.2 Neurology
   8.7.5.3 Oncology
   8.7.5.4 Thyroid
   8.7.5.5 Lymphoma
   8.7.5.6 Bone Metastasis
   8.7.5.7 Endocrine Tumor
   8.7.5.8 Pulmonary Scans
   8.7.5.9 Urology
   8.7.5.10 Othe
  8.7.6 Historic and Forecasted Market Size By End Use
   8.7.6.1 Hospitals
   8.7.6.2 Diagnostic Centers
   8.7.6.3 Others
  8.7.7 Historic and Forecast Market Size by Country
   8.7.7.1 Brazil
   8.7.7.2 Argentina
   8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research